NEUROMAGEN PHARMA

neuromagen-pharma-logo

Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS. Neuromagen Pharma was founded in 2021 and was headquartered in Beer Sheva, Israel.

#People #Website #More

NEUROMAGEN PHARMA

Industry:
Biopharma Biotechnology Neuroscience

Founded:
2021-01-01

Address:
Be'er Sheva, HaDarom, Israel

Country:
Israel

Website Url:
http://www.neuromagen.com

Status:
Active

Email Addresses:
[email protected]

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Content Delivery Network Font Awesome Global Site Tag


Current Employees Featured

gil-ben-menachem_image

Gil Ben Menachem
Gil Ben Menachem CEO & Co-Founder @ Neuromagen Pharma
CEO & Co-Founder
2021-07-01

Founder


gil-ben-menachem_image

Gil Ben Menachem

Official Site Inspections

http://www.neuromagen.com

  • Host name: do13.imark.co.il
  • IP address: 161.35.72.86
  • Location: New York United States
  • Latitude: 40.7157
  • Longitude: -74
  • Metro Code: 501
  • Timezone: America/New_York
  • Postal: 10013

Loading ...

More informations about "Neuromagen Pharma"

Neuromagen Pharma Ltd.

Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules which activate Telomerase Reverse Transcriptase (TERT) โ€“ an enzyme which โ€ฆSee details»

Neuromagen Pharma - Crunchbase Company Profile & Funding

Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS. Neuromagen Pharma was founded in 2021 and was headquartered in Beer Sheva, Israel.See details»

Neuromagen Pharma - VentureRadar

Website: https://www.neuromagen.com/ Develops innovative small molecules activating Telomerase Reverse Transcriptase, preventing cellular senescence and demonstrating โ€ฆSee details»

Neuromagen Pharma - PitchBook

Developer of a novel drug designed for the treatment of neurodegenerative diseases including amyotrophic lateral sclerosis. The company's drug boosts the effectiveness of telomerase as a โ€ฆSee details»

Neuromagen Pharma - Foreign Startup | Startup Nation Finder

Neuromagen Pharma is a pharmaceutical company developing a new class of innovative small molecules that activate telomerase reverse transcriptase (TERT), an enzyme that plays a โ€ฆSee details»

Neuromagen Pharma - LinkedIn

Neuromagen Pharma is an early-stage pharmaceutical company developing a new class of innovative small molecules which activate telomerase reverse transcriptase (TERT) โ€“ an enzyme which plays a...See details»

Neuromagen Pharma - Products, Competitors, Financials, โ€ฆ

Neuromagen Pharma is a pharmaceutical company focused on developing small molecule drugs for treating neurodegenerative diseases. Use the CB Insights Platform to explore Neuromagen โ€ฆSee details»

Neuromagen Pharma - Tech Stack, Apps, Patents & Trademarks

Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.See details»

Neuromagen Pharma - Crunchbase

Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.See details»

Neuromagen Pharma - Drug pipelines, Patents, Clinical trials

Explore Neuromagen Pharma with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Endocrinology and Metabolic Disease, Immune System Diseases, Nervous โ€ฆSee details»

Israeli drug that slowed Alzheimerโ€™s, ALS in mice gets โ€ฆ

Nov 2, 2021ย ยท They formed a company, Neuromagen Pharma, but did not have the funds to start the pre-clinical trials needed to prepare for human trials. Now, an Israeli funder has come up with the...See details»

Neuromagen Pharma Announces the Approval of a NIS 1.8M โ€ฆ

Mar 21, 2022ย ยท Neuromagen is developing a family of patent protected small molecule activators of telomerase reverse transcriptase โ€“ a key aging related enzyme which is associated with โ€ฆSee details»

Neuromagen Pharma - Contacts, Employees, Board Members

Neuromagen Pharma has 1 current employee profile, CEO & Co-Founder Gil Ben Menachem. Neuromagen Pharma develops drugs for neurodegenerative diseases including ALS.See details»

Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation โ€ฆ

May 5, 2022ย ยท Neuromagen Pharma Ltd. is an early-stage pharmaceutical company developing a new class of innovative small molecules which activate telomerase reverse transcriptase โ€ฆSee details»

Potential ALS drug gets boost toward preclinical trials

Nov 3, 2021ย ยท A new class of small molecules for treating amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigโ€™s Disease, and other neurodegenerative diseases, is being developed at โ€ฆSee details»

AGS-534 - Drug Targets, Indications, Patents - Synapse

AGS-534: a Telomerase activators Drug, Initially developed by Ben-Gurion University of the Negev, Now, its global highest R&D status is Preclinical, Mechanism: Telomerase โ€ฆSee details»

Neuromagen Pharma Ltd. Receives FDA Orphan Drug Designation โ€ฆ

05 May 2022 โ€“ Congratulations to Neuromagen Pharma Ltd. on their recent Orphan Drug Designation for AGS-499, its lead drug candidate. AGS-499 has shown significant โ€ฆSee details»

Gil Ben Menachem - CEO & Co-Founder @ Neuromagen Pharma

Gil Ben Menachem is the Co-Founder and CEO of Neuromagen Pharma. He previously worked at Kitov Pharma as a Vice President Of Business Development. Gil Ben Menachem attended the โ€ฆSee details»

Neuromagen Receives FDA Orphan Drug to Slow Progression of ALS

May 9, 2022ย ยท Israeli Neuromagen Pharma Ltd., a developer of drugs to treat degenerative and senescence-associated diseases, has received FDA Orphan Drug Designation for its lead โ€ฆSee details»